HS-20093 + anlotinib + epirubicin

HS-20093 + anlotinib + epirubicin is a combination regimen under clinical investigation for advanced solid tumors. HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) targeting B7-H3 (CD276), an immune checkpoint molecule overexpressed on many solid tumors. HS-20093 comprises an anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor as its cytotoxic payload. Anlotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against VEGFR, FGFR, PDGFR, and c-Kit, and is primarily used as an anti-angiogenic agent in cancer therapy. Epirubicin is an anthracycline antibiotic chemotherapeutic that intercalates DNA and inhibits topoisomerase II, leading to cytotoxic effects. The combination leverages targeted cytotoxicity (HS-20093), antiangiogenic and antiproliferative effects (anlotinib), and cytotoxic DNA damage (epirubicin). This investigational regimen is being assessed in a multi-arm phase 1/2 study in advanced solid tumors, focusing on safety, tolerability, pharmacokinetics, and preliminary antitumor activity[6].